Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Luzza

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Journal of Electrocardiology|August 14, 2022
Non-conducted premature atrial complexes: A new independent predictor of atrial fibrillation in cryptogenic strokeGiampaolo Vetta, Antonio Parlavecchio, Rodolfo Caminiti, et al.
Medicine|August 26, 2018
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centersAntonio Tursi, Walter Elisei, Roberto Faggiani, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|November 23, 2021
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with GolimumabAntonio Tursi, Giammarco Mocci, Walter Elisei, et al.
The American Journal of Gastroenterology|June 3, 2010
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled studyAntonio Tursi, Giovanni Brandimarte, Alfredo Papa, et al.
European Journal of Internal Medicine|June 19, 2019
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centersAntonio Tursi, Giammarco Mocci, Roberto Faggiani, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|October 1, 2011
Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) studyVincenzo De Francesco, Floriana Giorgio, Enzo Ierardi, et al.
European Journal of Gastroenterology & Hepatology|March 20, 2021
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatientsAntonio Tursi, Giammarco Mocci, Roberto Lorenzetti, et al.
Current Medical Research and Opinion|June 24, 2020
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern ItalyRoberta Roberti, Luigi Francesco Iannone, Caterina Palleria, et al.
Minerva Gastroenterology|March 1, 2023
Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndromeGiulia Fiorini, Ilaria M Saracino, Matteo Pavoni, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in ItalyAntonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Journal of Electrocardiology|August 14, 2022
Non-conducted premature atrial complexes: A new independent predictor of atrial fibrillation in cryptogenic strokeGiampaolo Vetta, Antonio Parlavecchio, Rodolfo Caminiti, et al.
Medicine|August 26, 2018
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centersAntonio Tursi, Walter Elisei, Roberto Faggiani, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|November 23, 2021
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with GolimumabAntonio Tursi, Giammarco Mocci, Walter Elisei, et al.
The American Journal of Gastroenterology|June 3, 2010
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled studyAntonio Tursi, Giovanni Brandimarte, Alfredo Papa, et al.
European Journal of Internal Medicine|June 19, 2019
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centersAntonio Tursi, Giammarco Mocci, Roberto Faggiani, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|October 1, 2011
Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) studyVincenzo De Francesco, Floriana Giorgio, Enzo Ierardi, et al.
European Journal of Gastroenterology & Hepatology|March 20, 2021
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatientsAntonio Tursi, Giammarco Mocci, Roberto Lorenzetti, et al.
Current Medical Research and Opinion|June 24, 2020
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern ItalyRoberta Roberti, Luigi Francesco Iannone, Caterina Palleria, et al.
Minerva Gastroenterology|March 1, 2023
Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndromeGiulia Fiorini, Ilaria M Saracino, Matteo Pavoni, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in ItalyAntonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.
Pageof 16